MMS Holdings and Oncology Trials Insights Form Strategic Partnership to Deliver Comprehensive Oncology Support Services

Canton, MI, August 18, 2014 --( MMS Holdings Inc., a global clinical research organization that focuses on regulatory submission support for the pharmaceutical, biotech and medical device industries, and Oncology Trials Insights (OTI), an organization of oncology key opinion leaders that architect superior clinical trial strategies and facilitate improved decision-making, today announced the creation of a strategic partnership to deliver comprehensive oncology support services.

“The partnership between MMS and OTI centers on our collective desire to improve the speed and efficiency of oncology drug development,” says Joseph Giglio, president & CEO of OTI. “MMS is widely recognized as a first-class, quality driven organization that clients choose to work with time and time again. By combining their robust services portfolio with our oncology-specific expertise, OTI and MMS have created an unmatched services offering, which is so desperately needed today.”

The strategic partnership will leverage MMS Holdings’ robust regulatory, clinical data management, medical writing, and biostatistics expertise with OTI’s protocol development, study site selection, and enrollment management services. This partnership will lead a unique oncology services that organizations can leverage to enhance their drug development pipeline and all of the aspects of their clinical trials.

“We are excited about the opportunity to collaborate with Oncology Trials Insights,” says Michelle Gayari, director of operations at MMS Holdings Inc. “Their oncology research experience and protocol development solutions were designed to accelerate oncology drug development for the benefit of cancer patients. Combining their industry leading expertise with our regulatory and clinical development experience will expedite the drug development process and lead to the creation of innovative cancer care treatments.”

About MMS Holdings Inc.

MMS Holdings Inc. is a clinical research organization that focuses on regulatory submission support for the pharmaceutical, biotech and medical device industries. Our strong industry experience and scientific approach to drug development makes us a valuable partner in creating compelling submissions that meet rigorous regulatory standards. Our clients span from top 10 pharma to virtual biotech's, and we support each one with the same standard of excellence. Our core service areas include Regulatory Operations, Data Management, Biostatistics, Clinical Programming, Medical and Regulatory Writing, Pharmacovigilance, Clinical Trial Disclosure and Oncology Data Abstraction. Commitment to quality deliverables sets MMS apart from traditional service providers. MMS is the only CRO to be ISO 9001 certified for all services since inception and we maintain detailed quality metrics for every project. For more information visit:

About Oncology Trials Insights

Oncology Trials Insights (OTI) is a clinical trials strategy company focused specifically in the oncology space. OTI was cofounded by key oncology opinion leaders and have recruited more than 70 of the world’s top oncology minds to work with the company. OTI focuses on identifying trial specific challenges and leveraging its clinical and operational resources to develop trial specific solutions. For more information visit:

Media Contacts:
Mike Gleeson
MMS Holdings, Inc.

Dave Espenshade
Oncology Trials Insights
MMS Holdings Inc.
Mike Gleeson